Beth Rogozinski is CEO at Oncoustics, an innovative AI diagnostics company that is creating low cost, non-invasive solutions for the detection and surveillance for diseases of the liver, kidney and pancreas. As a serial entrepreneur, technology professional, and business strategist, Beth has produced and published more than 30 games and apps, including over a dozen products for health and wellness. As Chief Product Officer at Pear Therapeutics, she led the development of Pear’s first clinical products and the product team submission of the De Novo 510k to the FDA. Pear’s ReSET™ was cleared by the FDA in 2017 as the first ever prescription digital therapeutic.